Previously only approved for adults, BioMarin’s pegvaliase-pqpz (PALYNZIQ) is now licensed for patients as young as 12 years.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-extends-approval-pku-drug-include-adolescents-2026a10006y2?src=rss
Author :
Publish date : 2026-03-06 11:44:00
Copyright for syndicated content belongs to the linked Source.
